ArticleMagma (New York, N.Y.)2025
A dual-stage framework for segmentation of the brain anatomical regions with high accuracy.
Article in Magma (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study presents a novel deep learning-based framework for precise brain MR region segmentation, aiming to identify the location and the shape details of different anatomical structures within the brain. MATERIALS AND
methodsThe approach uses a two-stage 3D segmentation technique on a dataset of adult subjects, including cognitively normal participants and individuals with cognitive decline. Stage 1 employs a 3D U-Net to segment 13 brain regions, achieving a mean DSC of 0.904 ± 0.060 and a mean HD95 of 1.52 ± 1.53 mm (a mean DSC of 0.885 ± 0.065 and a mean HD95 of 1.57 ± 1.35 mm for smaller parts). For challenging regions like hippocampus, thalamus, cerebrospinal fluid, amygdala, basal ganglia, and corpus callosum, Stage 2 with SegResNet refines segmentation, improving mean DSC to 0.921 ± 0.048 and HD95 to 1.17 ± 0.69 mm.
resultsStatistical analysis reveals significant improvements (p-value < 0.001) for these regions, with DSC increases ranging from 1.3 to 3.2% and HD95 reductions of 0.06-0.33 mm. Comparisons with recent studies highlight the superior performance of the performed method. DISCUSSION: The inclusion of a second stage for refining the segmentation of smaller regions demonstrates substantial improvements, establishing the framework's potential for precise and reliable brain region segmentation across diverse cognitive groups.
Indexed as
Identifiers
40042762What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.